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ET-I stimulated MBP kinase activity in cultured cardiomyocytes. Maximal activation (3.5-fold) was at 5 min. E&, was 0.2 nM. PMA or PE also 
increased MBP kinase (4- or 2.5-fold, respectively). Pre-treatment with PMA down-regulated the subsequent response to ET-l or PMA. ET-l- or 
PMA-stimulated MBP kinase was resolved into 2 major (peaks II and IV) and 2 minor peaks by FPLC on Mono Q. Peaks II and IV were inactivated 
by either LAR or PP2A. Renatured MBP kinase activities following SDS-PAGE in MBP-containing gels and immunoblot analysis showed that 
peak II was a p42 MAP kinase and peak IV was a p44 MAP kinase. 
Endothelin; Phorbol ester; cl,-Adrenergic agonist; Mitogen-activated protein kinase; Cultured neonatal rat ventricular cardiomyocyte; Cardiac 
hypertrophy 
1. INTRODUCTION 
The ventricular cardiomyocyte cultured from neona- 
tal rats is a valuable model system which, following 
exposure to appropriate agonists, exhibits many of the 
features of the hypertrophic response in the adult heart 
in vivo [l]. Hypertrophic agonists include the endothe- 
lins [2-4], ol,-adrenergic agonists [5-71 and tumour-pro- 
moting phorbol esters [7-91. Both ET-l and the 01,- 
adrenergic agonists stimulate phosphoinositide hydro- 
lysis [2,3,10], raise diacylglycerol concns. [2,1 l] and acti- 
vate PKC [7,12,13] in (mainly neonatal cardiomyocyte) 
cardiac preparations. These findings suggest an impor- 
tant role for PKC in the signal transduction mechanism 
of cardiac hypertrophy [l], a hypothesis supported by 
PKC transfection experiments [14]. However, details of 
the signalling events downstream from PKC remain 
poorly defined. Recently, the MAP kinases have been 
identified as ubiquitous [15] Ser/Thr protein kinases 
which are acutely activated in a variety of cells in re- 
sponse to mitogens [16-l 81 and which probably play a 
central role in diverse growth-related responses [19]. 
For full activation, MAP kinases require phosphoryla- 
tion on both Ser/Thr and Tyr residues [20,21]. Here, we 
demonstrate that hypertrophic agonists rapidly stimu- 
late the activity of two MAP kinases as well the activity 
of two uncharacterized MBP kinases. 
2. EXPERIMENTAL 
2.1. Myocyte isolation and culture 
Correspondence address. P.H. Sugden, Department of Cardiac Medi- 
cine, National Heart and Lung Institute, Dovehouse St., London SW3 
6LY, UK. Fax: (44) (71) 351 8113 or 376 3442. 
Abbreviations: ECL, enhanced chemiluminescence; ET, endothelin; 
FCS, foetal calf serum; FPLC, fast protein liquid chromatography; 
LAR, leukocyte common antigen-related protein tyrosine phosphat- 
ase; MAP kinase, mitogen-activated protein kinase; MBP, myelin 
basic protein; PBST, 0.05% (v/v) Tween-20 in phosphate-buffered 
saline; PE, phenylephrine; PKC, protein kinase C; PMA, phorbol 
12-myristate 13-acetate; PMSF, phenylmethanesulphonyl fluoride; 
PP2A, protein serinelthreonine phosphatase 2A; SDS-PAGE, sodium 
dodecyl sulphate-polyacrylamide g l electrophoresis; TCA, trichlo- 
roacetic acid. 
Hearts of I- to 2-day-old rats were digested with trypsin (Sigma type 
I) then with collagenase (Worthington type II) [22]. The resulting cell 
suspension (in medium 199 with Hank’s salts (Gibco) supplemented 
with 5 mg/ml glucose, 10% (v/v) heat-inactivated FCS and 0.1 mM 
bromodeoxyuridine) was enriched for cardiomyocytes by a prehmi- 
nary plating (30 min) during which time non-myocytes attached to the 
culture plates. Non-adhering cells were plated at density of 4.2 x 10) 
cells/mm’ in culture dishes (60 or 35 mm, Primaria, Falcon) and they 
began to beat spontaneously after l-2 d. The cardiomyocytes were 
maintained for 4 d before bromodeoxyuridine was withdrawn. After 
a further 2 d, FCS was replaced with insulin, transferrin, and vitamin 
Blz (Sigma, each at a final concentration of 1 mg/lOO ml) for 20-24 
h before use. Cardiomyocytes were exposed to agonists (all Sigma) as 
specified in serum-free medium at 37’C. The plates were rinsed 3 x 
with ice-cold Dulbecco’s phosphate buffered saline and scraped into 
ice-cold extraction buffer (20 mM B-glycerophosphate, 20 mM NaF, 
2 mM EDTA, 0.2 mM Na3V0,, 10 mM benzamidine, 25 @ml 
leupeptin, 50 pug/ml PMSF, 0.3% (v/v) mercaptoethanol, pH7.5). Ex- 
tracts were centrifuged for 10 min at 10 000 x g and 4°C and the 
supematant fractions retained. 
2.2. Assay of MBP kinase activity 
Protein kinase activity against MBP (Sigma) was assayed at 30°C 
in a final volume of 50 ~1 containing 15 mM /7-glycerophosphate, 0.28 
mg/ml MBP, 10 mM MgCI,, 50 mM NaF, 2 mM EDTA, 0.3 mM 
NajVO,, 2 PM CAMP dependent-protein kinase inhibitory peptide 
(TTYADFIASGRTGRRNAIHD, Bachem) and 120 PM [y-“P]ATP 
(Amersham, 40-100 Ci/mol, with which the reaction was initiated) at 
a final pH of 7.5. Reactions were terminated by spotting 40 ~1 of the 
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Fig. 1. Time course of MBP kinase stimulation m extracts of cultured 
neonatal cardiomyocytes. Cardiomyocytes (one 35 mm plate for each 
observation) were exposed to 1 PM TPA (0, solid line), 100 nM ET-I 
(m, dashed line) or 50 PM PE (A, solid line). Extracts were prepared 
and MBP kinase was assayed as described in section 2. Results 
(means + S.E., n = 334) are expressed relative to MBP kmase m ex- 
tracts from untreated cardiomyocytes. 
mixture onto 3MM papers (Whatman) that were immediately tm- 
mersed in 20% (v/v) TCA. Papers were washed (1 x 5 min. 3 x 30 min) 
m 20% TCA, then counted in 10 ml of Fluoran HV (Merck). 
3. RESULTS 
3.1. Activation of protein kinase activity in cardiomny- 
ocyte extracts 
Pre-treatment of cardiomyocytes with PMA, ET-I or 
PE stimulated MBP kinase activity maximally by 2.5 
to 4.5-fold in subsequently-isolated extracts (Fig. 1). 
Maximal activation occurred at 5 min. For ET-1 or PE, 
Table I 
Effect of pre-treatment of cardiomyocytes with PMA for 24 h on ET-I 
and PMA-stimulation of MBP kinase activity 
Pre-treatment with 
PMA (1 PM) 
Agonist MBP kinase activity 
(% control) 
None 
None 
ET-l (100 nM) 
ET-l (100 nM) 
PMA (I PM) 
PMA (1 PM) 
(100) 
121 & Sd 
293 f 18’ 
177 f 18b.C 
375 + 52’ 
206 f 23h,’ 
Cardromyocytes were pre-treated with PMA for 24 h when appropri- 
ate. One 35 mm plate was used for each observation Medium was 
removed and replaced with medium containing the appropriate ag- 
onist. After 5 min. extracts were prepared as described in section 2.1 
and assayed for MBP kinase activity as described m section 2.2. Re- 
sults are means I! S.E. for 3-4 separate preparations, Statistical signif- 
icance “P < 0.05, bP < 0.01. 'P < 0.001 vs. cardiomyocytes never ex- 
posed to PMA or other agonists; dP < 0.05, 'P < 0.01 for the effect of 
pre-treatment with PMA on the acute response to ET-I or PMA 
% 
r 100 ’ I 1 / I 
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Fig. 2. Dependence of MBP kinase sttmulatron on ET-I concentra- 
tion. Cardiomyocytes (one 35 mm plate for each observation) were 
exposed to ET-I for 5 min. Extracts were prepared and MBP kinase 
was assayed as described in section 2. Results (means f S.E.. n = 5) 
are expressed relative to activities m extracts from untreated cardio- 
(2-tailed Student’s r-test, n = 34). myocytes. 
the MBP kinase activity declined toward basal levels 
thereafter, whilst activation by PMA was sustained. The 
EC,, for ET-1 was 0.2 nM (Fig. 2). This value is similar 
to its Kd for its receptors [23,24] and its EC,, for stimu- 
lation of PI hydrolysis [2,3] and diacylglycerol accumu- 
lation [2]. 
Chronic treatment of cells with PMA down-regulates 
PKC, a manoeuvre that is useful in demonstrating the 
involvement of PKC in signalling pathways [25,26]. Pre- 
treatment of cardiomyocytes with PMA (1 PM) for 24 
h attentuated the stimulation of MBP kinase activity by 
ET-l or PMA (Table I). Although these findings are 
consistent with a role for PKC in the activation of MBP 
kinase, other unknown effects of PMA (e.g. were it 
down-regulates the ET receptor) may complicate this 
interpretation. 
3.2. FPLC of A4BP protein kinase activities 
FPLC of cardiomyocyte extracts on Mono Q col- 
umns revealed that two major (II and IV) and two 
minor (I and III) peaks of MBP kinase activities were 
stimulated by pre-treatment with 100 nM ET-l (Fig. 3). 
Peak II eluted at 0.20 M NaCl and activity was stimu- 
lated 4.1 + 0.5-fold (mean & SE, n = 5). Peak IV eluted 
at 0.25 M NaCl and was stimulated 5.7 ? 0.7-fold 
(n = 5). Peaks I and III eluted at 0.185 and 0.22 M 
NaCl, respectively. Apart from a small amount eluting 
in the flow-through before the start of the gradient, no 
other activity was eluted by up to 1 M NaCl (not 
shown). Extracts from cardiomyocytes exposed to 1 PM 
PMA for 5 min showed an identical profile (not shown) 
and stimulation was similar to ET-l (Peak II: 4.7 5 0.5- 
fold, Peak IV: 5.3 + O.&fold, n = 3). Peak II or IV did 
not phosphorylate histone HIS, casein or protamine 
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Fig. 3. FPLC of ET-l-stimulated MBP kinase. Cardiomyocytes were 
exposed to 100 nM ET-l for 5 min. Extracts (0.5 ml total from four 
60 mm plates) were prepared as described in section 2.1 and were 
applied to a Mono Q HR 5/5 column (Pharmacia LKB) equilibrated 
with 15 mM B-glycerophosphate, 1.5 mM EDTA, 0.1 mM Na,VO, 
and 1 mM dithiothreitol, pH 7.3 (Buffer A) at a flow rate of 1 mYmin. 
After washing with 5 ml of Buffer A, MBP kinase activity was eluted 
with a linear gradient of NaCl (o-O.35 M, dotted line) in Buffer A. 
Fractions (0.5 ml) were collected and assayed for MBP kinase as 
described in section 2.2. Typical elution profiles are shown for cells 
exposed to ET-l (m, solid line) or control conditions (e, dashed line). 
Similar elution profiles were obtained with 10 separate preparations 
of cardiomyocytes. 
(each at 5 mg/ml, Sigma, not shown). Because of their 
low activities, Peaks I and III were not examined fur- 
ther. 
60 25 50 75 10 0 
Time (mln) 
3.3. Inactivation of MBP kinase activities by protein 
phosphatases 
Peak II or IV MBP kinase was inactivated by incuba- 
tion with either the protein Tyr phosphatase LAR or 
with the protein SeriThr phosphatase PP2A (Fig. 4). 
This suggests phosphorylation of both Tyr and SerlThr 
residues is important in activation of these kinases, a 
characteristic of the MAP kinases [20,21]. 
3.4. Identification of peaks II and IV MBP kinases as 
p42 and p44 MAP kinases 
Fractions around Peaks II and IV from FPLC of 
ET- 1 -stimulated cardiomyocytes (Fig. 3) were exam- 
ined for their ability to phosphorylate MBP in gels 
[27,28] in situ (Fig 5a). Peak II (fraction 55) and Peak 
IV (fractions 67/68) had molecular masses of 42 and 44 
kDa, respectively (Fig. 5a). After concentration, SDS- 
PAGE and immunoblotting, Peaks II and IV showed 
immunoreactivity with an antiserum raised against an 
oligopeptide (ITVEEALAHPYLEQYYDPTFDEPV) 
corresponding to a common epitope in p42- and p44- 
MAP kinases [29]. Thus Peak II is probably a p42 MAP 
kinase and Peak IV is a p44 MAP kinase. Because 
> 90% of the MBP kinase in ET-l- or PMA-stimulated 
cardiomyocytes (Fig. 3) is MAP kinase (Fig. 5), results 
from the PKC down-regulation experiments (Table I) 
suggest hat activation of PKC is necessary for the acti- 
vation of MAP kinase. 
4. DISCUSSION 
The potent vasoconstrictor peptide ET-1 was initially 
isolated from the medium of aortic endothelial cell cul- 
01. ’ I ’ ’ 
00 25 50 75 10 0 
Time (mln) 
Fig. 4. Inactivation of MBP kinases by incubation with protein phosphatases. MBP kinase Peaks II or IV (Fig. 3) were buffer-exchanged by 
centrifugation through Sephadex G50 Supertine (Pharmacia NICK Spin columns) equilibrated with 50mM TrislHCl, 0.15 mM EGTA, 0.1% (v/v) 
mercaptoethanol and 1 mg/ml bovine serum albumin, pH 7.0, at 4°C in accordance with the manufacturer’s instructions. Samples were incubated 
at 30°C (final volume: 100 ~1) with PPZA (30 U/ml final, o, l ; 1 U of PPZA dephosphorylates 1nmol of phosphorylase u/min) in the presence 
(0) or absence (0) of 2 PM okadaic acid; or with LAR (0.1 mg/ml final, q , W) in the presence (0) or absence (B) of 1 mM Na,VO,. Samples (20 
~1) were withdrawn and 0.1 vol. of 40 PM okadaic acid (PPZA) or 20 mM Na,VO, (LAR) added. MBP kinase was assayed immediately as described 
in section 2.2 for peak II (Fig. 4a) or peak IV (Fig. 4b). Results are expressed relative to the mean of activities in assays containing the appropriate 
protein phosphatase inhibitors (okadaic acid or Na,VO,). Results from a single experiment are shown and similar results were obtained with another 
preparation of MBP kinases. 
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Fig. 5. Identification of MBP kinase peaks II and IV as MAP kinases. 
The numbers on the right of the panels refer to the molecular masses 
of marker proteins in kDa. In Fig 5a, MBP kinases were detected in 
situ in MBP-containing gels [27,28]. Fraction numbers (53356 and 
6669) are indicated across the bottom. Cardiomyocytes were exposed 
to 100 nM ET-l for 5 min and extracts were analysed by FPLC (Fig. 
3). SDS-PAGE sample buffer [20 ~1 containing 10% (w/v) SDS, 13% 
(v/v) glycerol, 0.3 M Tris/HCl, 0.2% (w/v) bromophenol blue, 0.13 M 
dithiothreitol. pH 6.81 was added to samples (40~1) of fractions with 
subsequent heating at 100°C for 5 min. Samples were then subjected 
to SDS-PAGE in a 10% polyacrylamide gel containing 0.5 mg/ml 
MBP. After electrophoresis, SDS was removed from the gel by wash- 
mg with 20% (v/v) 2-propanol in 50 mM Tris-HCI (pH 8.0). then 5 mM 
mercaptoethanol in 50 mM Tris-HC1 (pH 8.0). Proteins were further 
denatured by washing the gel in 6 M guanidine HCl, then renatured 
by extensive washes in 50 mM Tris-HCl (pH 8.0) containing 0.04% 
(v/v) Tween-40 and 5 mM mercaptoethanol at 4°C. After pre-incuba- 
tion of the gel at 20°C for 1 h in 40 mM HEPES, 2 mM dithiothreitol, 
10 mM MgCl,, pH 8.0, in situ phosphorylation of MBP was per- 
formed in 40 mM HEPES, 0.5 mM EGTA, 10 mM MgCl,, 2 ,uM 
TTYADFIASGRTGRRNAIHD, 40 PM [y-‘*P]ATP (5 pCi/ml, 25 
@X/gel), pH 8.0 at 2O’C for 3 h. After extensive washing in 5% (w/v) 
TCA and 10% (w/v) sodium pyrophosphate, gels were dried and au- 
toradiographed. 
tures [30]. In addition to its vasoconstrictor action, ET- 
1 has numerous trophic effects on cells (including the 
cardiomyocyte [11) and has recently been shown to acti- 
vate MAP kinases in mesangial cells [26]. An attractive 
hypothesis is that one role of ET-l in vivo is to function 
as a paracrine agent coupling local mechanical stimuli 
in the vascular bed (e.g. increases in pressure or flow) 
to the necessary hypertrophic adaptation of the cardio- 
myocyte [l]. ET-l may also have an autocrine function 
in the cardiomyocyte [31]. Equally, a common feature 
of conditions which induce cardiac hypertrophy in vivo 
is an increase in sympathetic tone and a role for c1,- 
adrenergic agonism has been proposed [32,33]. ET-I, 
ol,-adrenergic agonists and PMA induce responses char- 
acteristic of hypertrophy in cultured neonatal cardio- 
myocytes (increased protein per cell, accumulation and 
assembly of sarcomeres, activation of primary response 
genes, transcriptional activation of genes normally ex- 
pressed only in foetal heart, transcriptional activation 
of constitutively-expressed contractile protein genes) 
[l]. In adult cardiomyocytes, ET-l, a,-adrenergic ag- 
onists and PMA each acutely stimulate translation [34 
361. PKC is thus strongly implicated as a participant in 
the hypertrophic response [l]. In this regard, we have 
recently demonstrated that ET- 1, adrenaline and PMA 
each activate the major isoform of PKC (PKC-E) pres- 
ent in adult cardiomyocytes [13]. 
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In Fig 5b, MBP kinases were immunoblotted. Peaks II or IV from 
Mono Q chromatography of ET-l-stimulated cardiomyocytes (Fig. 3) 
were concentrated approx. IO-fold (Amicon microconcentrators), 
then subjected to SDS-PAGE in 10% (w/v) acrylamide gels. Gels were 
transferred to nitrocellulose using a Semi-Dry Transfer Cell (Bio-Rad) 
and immunoblotted with an antibody that recognises both p42 and 
p44 MAP kinases [29]. Non-specific sites were blocked with 5% non- 
fat milk in PBST for 1 h at room temperature, then primary antibodies 
(11500 dilution in the blocking solution) were incubated with the nitro- 
cellulose overnight at 4°C. After washing (3x5 mm) in PBST, nitrocel- 
lulose filters were incubated for 1 h at room temperature with the 
horse-radish-peroxidase-labelled s condary antibody (115000 dilution 
in 1% non-fat milk in PBST). After repeating the washing as described 
above, bound antibody was detected by the ECL method (Amersham) 
according to the manufacturer’s instructions. lmmunoblotting of sam- 
ples from an Independent experiment gave similar results. 
MAP kinases participate in a protein phosphoryla- 
tion cascade that is important in the transduction and 
transmission of extracellular signals to the nucleus [ 191, 
even though the phenotype following activation of 
MAP kinases may, for unknown reasons, be cell type- 
specific [19]. Several growth factors (e.g. nerve growth 
factor, epidermal growth factor) activate MAP kinases 
in other cell types [37,38]. We have now shown here 
ET- 1, PE and PMA activate p42 and p44 MAP kinases 
in cultured neonatal cardiomyocytes. There is also con- 
sistent activation of two further MBP kinases (Peaks I 
and III in Fig. 3) which we have not yet been able to 
characterize because of the small amounts of activity 
available. We cannot exclude the possibility that these 
are further members of the extended MAP kinase family 
[17]. Down-regulation of PKC attenuates activation of 
MAP kinases by ET-I or PMA and thus activation of 
PKC may be one pre-requisite for activation of MAP 
kinase under these conditions. Our results imply that 
activation of MAP kinases may be important in the 
development of cardiac hypertrophy. 
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